Caspofungin Acetate (Caspofungin Acetate) Patent Expiration, LOE Window & CMS Spending

Caspofungin Acetate (Caspofungin Acetate) by Fresenius Kabi: FDA Orange Book LOE 2032-12-21, 6 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $79 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN206110 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-12-21
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$309K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($79 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.